A251280 Stock Overview
Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Angiolab, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,110.00 |
| 52 Week High | ₩9,170.00 |
| 52 Week Low | ₩3,000.00 |
| Beta | 0 |
| 1 Month Change | 46.21% |
| 3 Month Change | -17.58% |
| 1 Year Change | -34.40% |
| 3 Year Change | -58.46% |
| 5 Year Change | -59.12% |
| Change since IPO | 9.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| A251280 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 24.8% | -4.0% | -3.3% |
| 1Y | -34.4% | 0.7% | 1.2% |
Return vs Industry: A251280 underperformed the KR Biotechs industry which returned 2.4% over the past year.
Return vs Market: A251280 underperformed the KR Market which returned 1.9% over the past year.
Price Volatility
| A251280 volatility | |
|---|---|
| A251280 Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A251280's share price has been volatile over the past 3 months.
Volatility Over Time: A251280's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Min-Young Kim | www.angiolab.co.kr |
Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis.
Angiolab, Inc. Fundamentals Summary
| A251280 fundamental statistics | |
|---|---|
| Market cap | ₩15.28b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A251280 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A251280 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A251280 perform over the long term?
See historical performance and comparison